Survival and prognostic factors in patients with hepatocellular carcinoma treated by percutaneous ethanol injection: A 10-year experience

Canadian Journal of Gastroenterology

Volumn 18, Issue 10, 2004, Pages 611-618

  Mazzanti, Roberto ^a   Arena, Umberto ^a   Pantaleo, Pietro ^a   Antonuzzo, Lorenzo ^a   Cipriani, Greta ^a   Neri, Bruno ^a   Giordano, Clara ^a   Lanini, Fabio ^a   Marchetti, Serena ^a   Gentilini, Paolo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Ablative therapy; Cirrhosis; Hepatocellular carcinoma; Percutaneous ethanol injection; Radiofrequency ablation; Transarterial chemoembolization

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TUMOR VOLUME;

EID: 8844231736     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/675972     Document Type: Article

References (50)

1. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable, hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-42.
2. Ryder SD; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003;52 (Suppl) 3:1-8.
3. Varela M, Sala M, Llovet JM, Bruix J. Treatment of hepatocellular carcinoma: Is there an optimal strategy? Cancer Treat Rev 2003;29:99-104.
4. Choti MA. Surgical management of hepatocellular carcinoma: Resection and ablation. J Vasc Interv Radiol 2002;13:S197-203.
5. Frilling A, Malago M, Broelsch CE. Current status of liver transplantation for treatment of hepatocellular carcinoma. Dig Dis 2001;19:333-7.
6. El-Serag HB. Hepatocellular carcinoma: An epidemiologic view. J Clin Gastroenterol 2002;35:S72-8.
7. Yao FY, Bass NM, Nikolai B, et al. Liver transplantation for hepatocellular carcinoma: Analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002;8:873-83.
8. Figueras J, Ibanez L, Ramos E, et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: Results of a multicenter study. Liver Transpl 2001;7:877-83.
9. Livraghi T. Radiofrequency ablation, PEIT, and TACE for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2003;10:67-76.
10. Daniele B, De Sin I, Izzo F, et al. Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: A Cancer of the Liver Italian Program (CLIP 08) retrospective case-control study. J Clin Gastroenterol 2003;36:63-7.
11. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
12. Lencioni RA, Allgaier HP, Cioni D, et al. Small Hepatocellular Carcinoma in Cirrhosis: Randomized comparison of radio-frequency thermal ablation versus percutancous ethanol injection. Radiology 2003;228:235-40.
13. Ahrar K, Gupta S. Hepatic artery embolization for hepatocellular carcinoma: Technique, patient selection, and outcomes. Surg Oncol Clin N Am 2003;12:105-26.
14. Yuen MF, Chan AO, Wong BC, et al. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: Results of a comparative study in 96 Chinese patients. Am J Gastroenterol 2003;98:1181-5.
15. O'Suilleabhain CB, Poon RT, Yong JL, Ooi GC, Tso WK, Fan ST. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 2003;90:325-31.
16. Bruix J, Castelts A, Montanya X, et al. Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: Need for controlled trials. Hepatology 1994;20:643-50.
17. Colleoni M, Audisio RA, De Braud F, Fazio N, Martinelli G, Goldhirsch A. Practical considerations in the treatment of hepatocellular carcinoma. Drugs 1998;55:367-82.
18. Hussain SA, Ferry DR, El-Gazzaz G, et al. Hepatocellular carcinoma. Ann Oncol 2001;12:161-72.
19. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002;359:1734-9.
20. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71.
21. Koda M, Murawaki Y, Mitsuda A, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: A randomized control study. Cancer 2001;92:1516-24.
22. Velazquez RF, Rodriguez M, Navascues CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003;37:520-7.
23. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellutar carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30.
24. A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients: The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-5.
25. Bruix J, Llovet JM. Prognostic assessment and evaluation of the benefits of treatment. J Clin Gastroenterol 2002;35:S138-42.
26. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000;31:840-5.
27. Leung TW, Tang AM, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: A study based on 926 patients. Cancer 2002;94:1760-9.
28. Ueno S, Tanabe G, Nuruki K, et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: A validation analysis. Hepatol Res 2002;24:395-403.
29. Zhao WH, Ma ZM, Zhou XR, Feng YZ, Fang BS. Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. World J Gastroenterol 2002;8:237-42.
30. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): Its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38:207-15.
31. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
32. Shiina S, Tagawa K, Unuma T, Terano A. Percutaneous ethanol injection therapy for the treatment of hepatocellular carcinoma. Am J Roentgenol 1990;154:947-51.
33. Liao CS, Yang KC, Yen MF, Teng LL, Duffy SW, Chen TH. Prognosis of small hepatocellular carcinoma treated by percutaneous ethanol injection and transcatheter arterial chemoembolization. J Clin Epidemiol 2002;55:1095-104.
34. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: Complications encountered in a multicenter study. Radiology 2003;226:441-51.
35. Koda M, Murawaki Y, Mitsuda A, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: A randomized control study. Cancer 2001;92:1516-24.
36. Gasparini D, Sponza M, Marzio A, Zanardi R, Bazzocchi M, Cemal Y. Combined treatment, TACE and RF ablation, in HCC: Preliminary results. Radiol Med 2002;104:412-20.
37. Kurokohchi K, Watanabe S, Masaki T, et al. Combined use of percutaneous ethanol injection and radiofrequency ablation for the effective treatment of hepatocelluar carcinoma. Int J Oncol 2002;21:841-6.
38. Huang YS, Chiang JH, Wu JC, Chang FY, Lee SD. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. Am J Gastroenterol 2002;97:1223-7.
39. Caturelli E, Siena DA, Fusilli S, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: Evaluation of damage to nontumorous liver tissue-long-term prospective study. Radiology 2000;215:123-8.
40. Kamada K, Kitamoto M, Aikata H, et al. Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma. Am J Surg 2002;184:284-90.
41. Mazzanti R, Giallombardo AL, Mini E, et al. Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: A pilot study. Dig Liver Dis 2004;36:278-85.
42. Colombo M, Sangiovanni A. Etiology, natural history and treatment of hepatocellular carcinoma. Antiviral Res 2003;60:145-50.
43. Fagiuali S, Mirante VG, Pompili M, et al. Liver transplantation: The Italian experience. Dig Liver Dis 2002;34:640-8.
44. Guyton KZ, Kensler TW. Prevention of liver cancer. Curr Oncol Rep 2002;4:464-70.
45. Sun HC, Tang ZY. Preventive treatments for recurrence after curative resection of hepatocellular carcinoma - a literature review of randomized control trials. World J Gastroenterol 2003;9:635-40.
46. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36:S74-83.
47. Mazzanti R, Messerini L, Monsacchi L, et al. Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis. Hepatology 1997;25:229-34.
48. Fox SB, Gasparini G, Harris AL. Angiogenesis: Pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol 2001;2:278-89.
49. Yachnin S. Demonstration of the inhibitory effect of human alpha-fetoprotein on in vitro transformation of human lymphocytes. Proc Natl Acad Sci USA 1976;73:2857-61.
50. Alpert E, Dienstag JL, Sepersky S, Littman B, Rocklin R. Immunosuppressive characteristics of human AFP: Effect on tests of cell mediated immunity and induction of human suppressor cells. Immunol Common 1978;7:163-85.